MSB 1.56% 97.5¢ mesoblast limited

Sorry thought I answered this - my reply seems not to have gone...

  1. 2,077 Posts.
    lightbulb Created with Sketch. 1185
    Sorry thought I answered this - my reply seems not to have gone through.

    The FDA is key performance indicated against the number of BLAs and BLA resubmissions it manages to do in a a period of a year or so - it has to report on those. This means it has to project manage so as to give itself the best chance to achieve a 6 month response time once it has accepted a resubmission for review.

    Booking and sending inspectors to Singapore would be something necessary to do unless it was already clear the BLA resubmission was going to fail. Presupposing failure - before taking a good look at all the details of the submission would be wrong - so booking and doing an inspection is just necessary to try to ensure the FDA can give a response in 6 months as its supposed to do.

    Reviewing all the info in BLA resubmission critically and fairly is a big project - it has to be handled with critical path analysis for the FDA to meet its time commitments - that why in my opinion.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
97.5¢
Change
0.015(1.56%)
Mkt cap ! $1.113B
Open High Low Value Volume
97.0¢ 99.5¢ 97.0¢ $2.315M 2.360M

Buyers (Bids)

No. Vol. Price($)
9 119971 97.5¢
 

Sellers (Offers)

Price($) Vol. No.
99.0¢ 24889 9
View Market Depth
Last trade - 16.10pm 22/08/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.